Sen. Grassley Requests Information On Delay Of Results Of Study On Cholesterol Medication Vytorin
Senate Finance Committee ranking member Chuck Grassley (R-Iowa) on Monday sent a letter to the CEOs of Merck and
Trans Fat: Why It's Time To Eliminate This Dietary Villain
Trans fats are a cholesterol double whammy. Also known as trans fatty acids, trans fats raise low-density lipoprotein (LDL or "bad") cholesterol and lower high-density lipoprotein (HDL or "good") cholesterol.Experts consider trans fat the worst type of dietary fat.
Pieces Coming Together In Parkinson's, Cholesterol Puzzle
In 2006, University of North Carolina at Chapel Hill researchers published a study that found people with low levels of LDL cholesterol are more likely to have Parkinson's disease than people with high LDL levels.But that study could not answer the question of whether low LDL (low-density lipoprotein) levels were present in study participants before they were diagnosed with Parkinson's, or if they developed low LDL levels after being diagnosed.
Levitra reg; Therapy Suitable For Men With High Cholesterol
At the 23rd Annual European Association of Urology (EAU) Congress, results were presented which added evidence that Levitra (vardenafil HCI) works very well in men with dyslipidemia.(1) The double-blind, placebo-controlled trial in about 400 men showed that Levitra significantly improved the ability of men with erectile dysfunction (ED) and high cholesterol, to achieve and maintain an erection for successful sexual intercourse.
Lower Blood Pressure Linked To Statins
An article published in the Archives of Internal Medicinereports that statins - medications that are usually prescribed to lowerblood cholesterol levels - may also lower blood pressure. Beatrice A.Golomb, M.D., Ph.D., (University of California, San Diego, La Jolla)and colleagues noted a modest but significant reduction in bloodpressure for patients taking statins.
Two Merck Medicines Recommended For Approval In The European Union
Merck & Co., Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended two medicines for marketing approval in the European Union (EU). The CHMP recommended marketing approval for TREDAPTIVE™
FDA Provides Clarity To Isis Regarding The Development Path For Mipomersen
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Genzyme Corp. (Nasdaq: GENZ) announced that the FDA has provided guidance regarding approval requirements for mipomersen. The FDA has indicated that reduction of LDL-cholesterol is an acceptable surrogate endpoint for accelerated approval of mipomersen for use in patients with homozygous familial hypercholesterolemia (hoFH).
Higher Cholesterol Increases Risk Of Boichemical Failure After Radical Prostatectomy
Poor cholesterol management may not only affect a man's risk for prostate cancer, but also his risk of biomedical recurrence after prostatectomy, according to new data from Duke University.
Analysis: Control Reduces Cardiovascular Risk By 42
Results of a new analysis of the Treating to New Targets (TNT) study show that intensive low-density lipoprotein (LDL) cholesterol-lowering in patients with stable coronary heart disease (CHD) whose systolic blood pressure was less than 140 mmHg reduced the risk of major cardiovascular events, including heart attack, stroke and resuscitated cardiac arrest, by 42 percent compared with less intensive LDL lowering and uncontrolled blood pressure of 140 mmHg or higher.
5 Tips To Increase HDL Cholesterol
Thanks to powerful cholesterol-lowering statin drugs, driving down low-density lipoprotein (LDL), or "bad" cholesterol, has been the primary approach to improving cholesterol levels. But there's more to the story of cholesterol and cardiovascular risk than LDL alone.